Cargando…

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

The goal of this narrative review was to summarize immunogenicity data of biosimilars or biosimilar candidates for rheumatic diseases, plaque psoriasis, or inflammatory bowel disease (IBD), available in peer-reviewed publications or regulatory documents. PubMed records and regulatory documents were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Gonçalves, Joao, Hickling, Timothy P., Jones, Heather E., Marshall, Lisa, Isaacs, John D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042210/ https://www.ncbi.nlm.nih.gov/pubmed/31721107 http://dx.doi.org/10.1007/s40259-019-00394-x

Ejemplares similares

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents
por: Strand, Vibeke, et al.
Publicado: (2020)

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis
por: Bellinato, Francesco, et al.
Publicado: (2022)

Biologics and Biosimilars in Psoriasis
por: Ahmed, Sk Shahriar, et al.
Publicado: (2023)

Biosimilars in paediatric inflammatory bowel disease
por: Sieczkowska-Golub, Joanna, et al.
Publicado: (2018)

The changing landscape of biosimilars in rheumatology
por: Dörner, Thomas, et al.
Publicado: (2016)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Addressing unmet clinical needs: the potential of biosimilars in the treatment of rheumatic diseases
por: Schulze-Koops, Hendrik
Publicado: (2017)

Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world
por: Sung, Yoon-Kyoung, et al.
Publicado: (2020)

Current status of biosimilars in the treatment of inflammatory bowel diseases
por: Park, Dong Il
Publicado: (2016)

Insights on the use of biosimilars in the treatment of inflammatory bowel disease
por: Zheng, Michael K, et al.
Publicado: (2017)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective
por: Kurki, Pekka, et al.
Publicado: (2021)

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
por: Doevendans, Erik, et al.
Publicado: (2019)

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council
por: Cohen, Arnon D., et al.
Publicado: (2020)

Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry
por: Nabi, Hafsah, et al.
Publicado: (2022)

Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review
por: Strand, Vibeke, et al.
Publicado: (2017)

Regulatory Considerations for Biosimilars
por: Nellore, Ranjani
Publicado: (2010)

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab
por: Fischer, Sarah, et al.
Publicado: (2021)

Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars
por: Hakizimana, Ali, et al.
Publicado: (2017)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Real-life Efficacy and Safety of Biosimilar Adalimumab (ZRC-3197) in Patients with Plaque Psoriasis: A Tertiary Care Center Experience
por: Chopra, Ajay, et al.
Publicado: (2020)

Biosimilars in inflammatory bowel disease: A review of post-marketing experience
por: Deiana, Simona, et al.
Publicado: (2017)

Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases
por: Park, Sang Hyoung, et al.
Publicado: (2020)

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients
por: Garcia, Karoline Soares, et al.
Publicado: (2021)

Emerging role of biosimilars in the clinical care of inflammatory bowel disease patients
por: Najeeb, Hala, et al.
Publicado: (2022)

Biosimilar Drugs for Psoriasis: Principles, Present, and Near Future
por: Carrascosa, Jose-Manuel, et al.
Publicado: (2018)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Antibody responses after documented COVID-19 disease in patients with autoimmune rheumatic disease
por: Shenoy, Padmanabha, et al.
Publicado: (2021)

Immunogenicity of biologics in inflammatory bowel disease
por: Vermeire, Séverine, et al.
Publicado: (2018)

Guselkumab for plaque psoriasis
Publicado: (2019)

Bimekizumab for plaque psoriasis
Publicado: (2022)

Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model
por: Kvist, Peter H, et al.
Publicado: (2009)

The Influence of Corticosteroids, Immunosuppressants and Biologics on Patients With Inflammatory Bowel Diseases, Psoriasis and Rheumatic Diseases in the Era of COVID-19: A Review of Current Evidence
por: Zhang, Mengyuan, et al.
Publicado: (2021)

Imbalanced machine learning classification models for removal biosimilar drugs and increased activity in patients with rheumatic diseases
por: Castro Corredor, David, et al.
Publicado: (2023)

Effectiveness of infliximab biosimilars in the treatment of moderate to severe chronic plaque psoriasis: experience of real-world data from the register of the program “Treatment of moderate and severe forms of plaque psoriasis (B.47)” of the National Health Fund in Poland
por: Owczarek, Witold, et al.
Publicado: (2021)

Regulatory B cells in autoimmune rheumatic diseases
por: Sakkas, Lazaros I.
Publicado: (2017)

Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives
por: Rawla, Prashanth, et al.
Publicado: (2018)

Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
por: Milassin, Ágnes, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_4d3vjs10qp2hubucq4m47n1gbp